Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 MRNA COVID-19 vaccine: Real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal, Hila Ben-Amram, Karine Beiruti, Yunis Batheesh, Christian Sussan, Salman Zarka, Michael Edelstein

Research output: Contribution to journalArticlepeer-review

203 Scopus citations

Abstract

The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicity was similar by ethnicity and sex but decreased with age. Those with prior infection had antibody titres one magnitude order higher than naïve individuals regardless of the presence of detectable IgG antibodies pre-vaccination.

Original languageEnglish
JournalEurosurveillance
Volume26
Issue number6
DOIs
StatePublished - Feb 2021

Bibliographical note

Publisher Copyright:
© 2021 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

Fingerprint

Dive into the research topics of 'Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 MRNA COVID-19 vaccine: Real-world evidence from healthcare workers, Israel, December 2020 to January 2021'. Together they form a unique fingerprint.

Cite this